Pharmaceutical Laws and Regulations in Japan
Pharmaceutical laws and regulations in Japan are designed to ensure the quality, efficacy and safety of pharmaceuticals, medical devices and other regulated healthcare products. The Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) have central and complementary roles within this regulatory framework.
Pharmaceutical Laws and Regulations in Japan: PMD Act
The principal legislation is the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, commonly known as the Pharmaceuticals and Medical Devices Act (PMD Act). It replaced the former Pharmaceutical Affairs Act terminology and provides the legal framework for regulating pharmaceuticals, medical devices, regenerative medical products and other regulated products in Japan.
The PMD Act covers important areas such as product approval, manufacturing and marketing requirements, quality and safety controls, labeling, advertising and post-marketing safety measures. The legislation is periodically amended as Japan’s regulatory system evolves.
Current information on pharmaceutical and medical-device regulation is available from the Ministry of Health, Labour and Welfare (MHLW).
Japan’s Pharmaceutical Regulatory Authorities: MHLW and PMDA
MHLW is responsible for pharmaceutical and medical-device regulatory policy and administrative oversight. PMDA supports the regulatory system through scientific reviews, regulatory consultations, inspections and post-marketing safety activities.
For new pharmaceuticals, PMDA conducts scientific reviews of submitted data relating to quality, efficacy and safety. Regulatory decisions are made within Japan’s statutory framework, with approval for new drugs granted by the Minister of Health, Labour and Welfare.
For more background on the Ministry’s responsibilities, see Organization and Functions of MHLW in Japan.
Clinical Trial Regulations and GCP in Japan
Clinical trials intended to support regulatory submissions in Japan are subject to applicable requirements under the PMD Act and Good Clinical Practice (GCP). Sponsors must comply with requirements relating to study conduct, participant protection, safety reporting, documentation and data reliability.
Japan also has a separate Clinical Trials Act, which applies to specified categories of clinical research and should be distinguished from GCP trials conducted for marketing-authorization purposes.
Manufacturing and Quality
Pharmaceutical manufacturers and marketing authorization holders must comply with applicable quality requirements, including Good Manufacturing Practice (GMP). Regulatory inspections and quality-system requirements help ensure that pharmaceutical products are consistently manufactured and controlled according to established standards.
Post-Marketing Safety
Japan maintains an extensive post-marketing safety system. Once a product is marketed, safety information continues to be collected, evaluated and communicated. MHLW and PMDA may implement safety measures when new risks are identified, including revisions to precautions and other risk-management actions.
Labeling and Advertising
Pharmaceutical labeling and promotional activities are subject to regulatory requirements intended to ensure appropriate product information and prevent false, exaggerated or misleading claims.
Japan’s pharmaceutical regulatory framework therefore covers the product lifecycle from development and clinical investigation through regulatory review, manufacturing, marketing and post-marketing safety surveillance. Understanding pharmaceutical laws and regulations in Japan is essential for navigating regulatory requirements throughout the pharmaceutical product lifecycle.
You may be interested in the programs below:
